**BridgeBio Pharma, Inc. Reports 2025 Financial Results and Outlines Strategic Priorities**
BridgeBio Pharma, Inc. (BBIO) reported total revenues of $502.1 million for the fiscal year 2025, a significant increase compared to $221.9 million in 2024. This growth was primarily driven by $362.4 million in net product revenue from Attruby (acoramidis) in the U.S., following its FDA approval in November 2024, and $128.3 million in license and services revenue, partially offset by $11.4 million in royalty revenue. The company's net loss for 2025 was $732.9 million, compared to a net loss of $543.3 million in the previous year. Research and development expenses totaled $452.0 million, a decrease from $506.5 million in 2024, while selling, general, and administrative expenses increased to $531.2 million from $288.9 million in the prior year, reflecting the commercial launch of Attruby.
A key strategic development in 2025 was the commercial success of Attruby, which achieved over 7,800 unique patient prescriptions and penetration into over 1,850 prescribing healthcare professionals in the U.S. Beyonttra, the brand name for acoramidis outside the U.S., also demonstrated strong early uptake in Europe, particularly in Germany, where it captured over 50% of the new-to-brand prescription share within its first year. The company also highlighted positive Phase 3 results for infigratinib in achondroplasia, encaleret in ADH1, and BBP-418 in LGMD2I/R9, with plans to submit NDAs to the FDA in the first half of 2026. International approvals for Beyonttra in Europe, the UK, and Japan further expanded the company's global commercial footprint.
Operationally, BridgeBio reported significant progress in its key business indicators. The company's commercial organization focused on supporting the appropriate use of Attruby and Beyonttra in approved markets. The company also emphasized its commitment to early-stage development, including expansion indications and the initiation of a registrational study of encaleret in chronic hypoparathyroidism and pediatric ADH1 in 2026, alongside studying infigratinib for hypochondroplasia in 2027. The company also maintains minority equity interests in GondolaBio, LLC and BridgeBio Oncology Therapeutics, Inc., which are separate companies spun out of BridgeBio and allows the company to retain exposure to a broad pipeline of early-stage development opportunities, while remaining focused on advancing and commercializing its core portfolio.
Looking ahead, BridgeBio anticipates progressing its Phase 3 programs towards anticipated approvals in the U.S. and Europe, actively preparing for worldwide commercial launches of these products, if approved. The company also plans to continue its collaborations with Bayer and Alexion to drive continued growth in Europe and Japan, respectively. BridgeBio's financial performance is expected to be influenced by the commercial success of Attruby and Beyonttra, as well as the potential launch of three additional medicines globally. The company's estimates of expenses, ongoing losses, capital requirements, and use of cash resources will also play a crucial role in its financial outlook.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. is a biopharmaceutical company focused on discovering, developing, and delivering transformative medicines for genetic diseases. Its core products include Attruby/Beyonttra, an oral therapy for transthyretin amyloid cardiomyopathy, and late-stage clinical candidates targeting achondroplasia, autosomal dominant hypocalcemia, and limb girdle muscular dystrophy. BridgeBio leverages genetic insights and innovative drug platforms to address high unmet medical needs, serving patients through regulatory approvals and strategic partnerships.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.